Institutional members access full text with Ovid®

Expression of Squamous Cell Carcinoma Markers and Adenocarcinoma Markers in Primary Pulmonary Neuroendocrine Carcinomas

Masai, Kyohei MD*,†; Tsuta, Koji MD, PhD*; Kawago, Mitsumasa MD*,†; Tatsumori, Takahiro MD*; Kinno, Tomoaki MD*; Taniyama, Tomoko MD*; Yoshida, Akihiko MD, PhD*; Asamura, Hisao MD, PhD; Tsuda, Hitoshi MD, PhD*

Applied Immunohistochemistry & Molecular Morphology: July 2013 - Volume 21 - Issue 4 - p 292–297
doi: 10.1097/PAI.0b013e31826fd4f3
Research Articles

Recent clinical trials have revealed that accurate histologic typing of non–small cell lung cancer is essential. Until now, squamous cell carcinoma (SQC) and adenocarcinoma (ADC) markers have not been thoroughly analyzed for pulmonary neuroendocrine carcinomas (NECs). We analyzed the expression of 8 markers [p63, cytokeratin (CK) 5/6, SOX2, CK7, desmocollin 3, thyroid transcription factor-1 (8G7G3/1 and SPT24), and napsin A] in 224 NECs. SOX2 (76.2%) had the greatest expression for NECs. CK5/6 (1.4%), desmocollin 3 (0.5%), and napsin A (0%) were expressed less or not at all in NECs. Although our investigated markers have been reported useful for differentiating between SQC and ADC, some of them were also present in a portion of pulmonary NECs. In our study, CK5/6 and desmocollin 3 were highly specific markers for SQC, and napsin A was highly specific for ADC. These markers are recommended for diagnosis of poorly differentiated non–small cell lung cancer.

Divisions of *Pathology and Clinical Laboratory

Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan

Supported in part by the National Cancer Center Research and Development Fund (23-A-2), (23-A-11), and (23-A-35).

The authors declare no conflict of interest.

Reprints: Koji Tsuta, MD, PhD, Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan (e-mail: ktsuta@ncc.go.jp).

Received June 27, 2012

Accepted August 18, 2012

© 2013 Lippincott Williams & Wilkins, Inc.